ZIOPHARM Oncology Inc.  

(Public, NASDAQ:ZIOP)   Watch this stock  
Find more results for ZIOP
13.81
+0.47 (3.52%)
After Hours: 13.76 -0.05 (-0.36%)
Mar 5, 7:02PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.40 - 14.27
52 week 2.31 - 14.27
Open 13.79
Vol / Avg. 7.98M/4.61M
Mkt cap 1.52B
P/E     -
Div/yield     -
EPS -0.31
Shares 112.68M
Beta 1.79
Inst. own 39%
May 6, 2015
Q1 2015 ZIOPHARM Oncology Inc Earnings Release (Estimated) Add to calendar
Feb 26, 2015
Q4 2014 ZIOPHARM Oncology Inc Earnings Release
Feb 10, 2015
ZIOPHARM Oncology Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 14, 2015
ZIOPHARM Oncology Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -3059.12% -2314.71%
Operating margin -3116.47% -3168.17%
EBITD margin - -3134.52%
Return on average assets -88.44% -54.33%
Return on average equity -118.66% -76.37%
Employees 27 -
CDP Score - -

Address

Parris Building, #34, 1 First Avenue
BOSTON, MA 02129
United States - Map
+1-617-2591970 (Phone)
+1-617-2412855 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ZIOPHARM Oncology, Inc. is a biotechnology company employing gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System technology to turn on and off, and modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company's synthetic immuno-oncology programs in collaboration with Intrexon also include chimeric antigen receptor T cell (CAR-T) approaches.

Officers and directors

Jonathan Lewis MD, Ph.D Chief Executive Officer, Director
Bio & Compensation  - Reuters
Kevin G. Lafond CPA Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 58
Bio & Compensation  - Reuters
Caesar J. Belbel Executive Vice President, Chief Legal Officer, Secretary
Age: 54
Bio & Compensation  - Reuters
Murray Brennan Non-Executive Lead Independent Director
Age: 74
Bio & Compensation  - Reuters
Randal J. Kirk Director
Age: 60
Bio & Compensation  - Reuters
James A. Cannon Independent Director
Age: 75
Bio & Compensation  - Reuters
Wyche Jr Fowler Jr., J.D Independent Director
Age: 73
Bio & Compensation  - Reuters
Timothy McInerney Independent Director
Age: 53
Bio & Compensation  - Reuters